Table 2.
Baseline characteristics of reclassified and non-reclassified individuals when changing from the 2009 to 2021 equation
| All individuals (N = 1 601 237) | Individuals with CKD G3–5 with the 2009 equation (N = 81 674) | |||
|---|---|---|---|---|
| Characteristic | Reclassified to a higher eGFR category (N = 158 944) | Not reclassified (N = 1 442 293) | Reclassified to a higher eGFR category (N = 29 581) | Not reclassified (N = 52 093) |
| Mean age (SD), years | 62 (16) | 46 (18) | 77 (12) | 77 (13) |
| Age category, n (%) | ||||
| <50 years | 37 454 (24) | 869 312 (60) | 860 (3) | 2368 (5) |
| 50–59 years | 27 576 (17) | 223 430 (15) | 1669 (6) | 2666 (5) |
| 60–69 years | 39 668 (25) | 184 989 (13) | 4614 (16) | 6872 (13) |
| 70–79 years | 36 647 (23) | 88 856 (6) | 8553 (29) | 13 305 (26) |
| ≥80 years | 17 599 (11) | 75 706 (5) | 13 885 (47) | 26 882 (52) |
| Female sex, n (%) | 80 067 (50) | 774 139 (54) | 17 435 (59) | 31 264 (60) |
| Mean plasma creatinine (SD), μmol/La | 80 (21) | 73 (23) | 104 (30) | 130 (75) |
| eGFR with the 2009 equation, mL/min/1.73 m2 | 81 (14) | 98 (21) | 53 (9) | 44 (11) |
| eGFR with the 2021 equation, mL/min/1.73 m2 | 86 (15) | 102 (20) | 57 (10) | 47 (12) |
| Education, n (%) | ||||
| Compulsory school | 33 973 (22) | 228 433 (16) | 10 370 (37) | 19 427 (39) |
| Secondary school | 60 681 (39) | 553 645 (39) | 10 759 (38) | 18 898 (38) |
| University | 60 535 (39) | 633 786 (45) | 7009 (25) | 10 875 (22) |
| Medical history, n (%) | ||||
| Hypertension | 40 768 (26) | 187 345 (13) | 14 342 (48) | 27 650 (53) |
| Myocardial infarction | 5943 (4) | 24 795 (2) | 2817 (10) | 6065 (12) |
| Other ischemic heart disease | 12 595 (8) | 50 921 (4) | 5750 (19) | 11 777 (23) |
| Heart failure | 8083 (5) | 31 153 (2) | 5284 (18) | 12 268 (24) |
| Stroke | 6906 (4) | 28 571 (2) | 3251 (11) | 6673 (13) |
| Other cerebrovascular disease | 6079 (4) | 25 305 (2) | 2854 (10) | 5868 (11) |
| Arrhythmia | 13 442 (8) | 61 567 (4) | 6194 (21) | 12 447 (24) |
| Peripheral vascular disease | 3172 (2) | 14 073 (1) | 1568 (5) | 3473 (7) |
| Diabetes | 13 059 (8) | 72 208 (5) | 4620 (16) | 9656 (19) |
| Cancer | 6920 (4) | 33 063 (2) | 2150 (7) | 4096 (8) |
| Chronic obstructive pulmonary disease | 5417 (3) | 22 690 (2) | 1904 (6) | 3814 (7) |
| Liver disease | 2006 (1) | 18 490 (1) | 471 (2) | 954 (2) |
| Concomitant medications, n (%) | ||||
| Beta blocker | 28 809 (18) | 132 472 (9) | 10 860 (37) | 21 400 (41) |
| Calcium channel blocker | 14 842 (9) | 65 105 (5) | 5138 (17) | 10 135 (19) |
| Diuretic | 21 212 (13) | 88 947 (6) | 10 950 (37) | 23 737 (46) |
| RASi | 27 599 (17) | 127 590 (9) | 9642 (33) | 19 603 (38) |
| Lipid-lowering drug | 21 924 (14) | 95 617 (7) | 6722 (23) | 12 717 (24) |
| NSAIDs | 22 259 (14) | 178 010 (12) | 4101 (14) | 7090 (14) |
| Calendar year, n (%) | ||||
| 2007–10 | 115 430 (73) | 882 148 (61) | 25 694 (87) | 45 943 (88) |
| 2011–14 | 25 314 (16) | 321 304 (22) | 2278 (8) | 3546 (7) |
| 2015–19 | 18 200 (11) | 238 841 (17) | 1609 (5) | 2604 (5) |
n = number; eGFR = estimated glomerular filtration rate; RASi = renin-angiotensin system inhibition (angiotensin-converting enzyme inhibitor or angiotensin receptor blocker); NSAIDs = non-steroidal anti-inflammatory drugs.
a
Mean (SD) plasma creatinine is 0.90 (0.24) mg/dL for reclassified and 0.83 (0.26) mg/dL for non-reclassified individuals. To convert plasma creatinine from μmol/L to mg/dL, multiply by 0.0113.